Condition
Benign Masseteric Hypertrophy
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (2)
Trial Status
Completed2
Unknown1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05964257Phase 3Active Not RecruitingPrimary
To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy
NCT04294251Phase 3CompletedPrimary
Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy
NCT04443244Phase 2CompletedPrimary
Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy
NCT03369990Phase 2UnknownPrimary
DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy
Showing all 4 trials